cefotiam (ceradon) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Cefotiam is a third generation beta-lactam cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. The bactericidal activity of cefotiam results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).   NCATS

Chemistry

  • SMILES: CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1
  • InChIKey: QYQDKDWGWDOFFU-IUODEOHRSA-N
  • Mol. Mass: 525.64
  • ALogP: -0.65
  • ChEMBL Molecules:
    cefotiam  
    cefotiam hydrochloride  
More Chemistry

Pharmacology

Alternative names

(6r,7r)-7-[2-(2-amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1h-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid | abbott-48999 | cefotiam | cefotiam hcl | cefotiam hexetil | cefotiam hexetil hcl | cefotiam hexetil hydrochloride | cefotiam hydrochloride | cefotiamum | ceradon | cgp-14221/e | ctm | pansporin | sce-963

Organizations (8)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Cystitis (approved 1987)

Respiratory Tract Infections (approved 1987)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Overview

  • Highest Phase: N/A
  • # of Trials: 2
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue